Having trouble viewing this email? View it as a Web page.
You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
03/06/2024 10:30 AM EST
NIH-funded research networks provide evidence on cabotegravir and rilpivirine in additional populations.
| Update Your E-mail Address | Add Subscriptions | Unsubscribe All If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view ourFrequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health.
|
| This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) 9000 Rockville Pike Bethesda MD 20892 301-496-4000 / TTY 301-402-9612 |  |
